...
首页> 外文期刊>Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia >CyberKnife radiosurgery for acoustic neuromas: Tumor control and clinical outcomes
【24h】

CyberKnife radiosurgery for acoustic neuromas: Tumor control and clinical outcomes

机译:用于声学神经瘤的Cyber Knife放射牢:肿瘤控制和临床结果

获取原文
获取原文并翻译 | 示例
           

摘要

Fractionated CyberKnife radiosurgery (CKRS) treatment for acoustic neuromas may reduce the risk of long-term radiation toxicity to nearby critical structures compared to that of single-fraction radiosurgery. However, tumor control rates and clinical outcomes after CKRS for acoustic neuromas are not well described. We retrospectively reviewed all acoustic neuroma patients treated with CKRS (2004-2011) in a prospectively maintained clinical and radiographic database. Treatment failure, the need for additional surgical intervention, was evaluated using Kaplan-Meier analysis. For 119 treated patients, median values were 49 months (range, 6-133 months) of follow-up, 1.6 cm(3) (range, 0.02-17 cm(3)) tumor volume, and 18 Gy (range, 13-25 Gy) prescribed dose delivered in 3 fractions (range, 1-5 fractions). Thirty-five of 59 patients (59%) with pre-radiosurgery serviceable hearing (American Academy of Otolaryngology Head and Neck Surgery class A or B) maintained serviceable hearing at the last audio follow-up (median, 21 months). Two of 111 patients (2%) with facial nerve function House-Brackmann (HB) grade 3 after radiosurgery. Moos grade IV was predictive of radiographic tumor growth after radiosurgery compared to grades I to III (p = 0.02). Treatment failure occurred in 9 of 119 patients (8%); median time to failure was 29 months (range, 4-70 months). The actuarial rates of tumor control at 1, 3, 5, and 7 years were 96%, 94%, 88%, and 88%, respectively. CKRS affords effective tumor control for acoustic neuromas with an acceptable rate of hearing preservation. Further studies are needed to compare CKRS to single-fraction radiosurgery for acoustic neuromas. (C) 2019 Elsevier Ltd. All rights reserved.
机译:与单级分术放射外科的相比,分级瘤神经瘤的分馏克明术(CKRS)治疗可能会降低对附近的关键结构的长期辐射毒性的风险。然而,对声学神经瘤的CKRS后肿瘤对照率和临床结果也没有很好地描述。我们回顾性地审查了在预期维护的临床和放射线测量数据库中使用CKRS(2004-2011)治疗的所有声学神经瘤患者。治疗失败,使用Kaplan-Meier分析评估了对额外的外科干预的需求。对于119名治疗患者,中值值为49个月(范围,6-133个月)的随访,1.6厘米(3)(范围,0.02-17厘米(3))肿瘤体积,18 GY(范围,13- 25 GY)在3个级分中递送的规定剂量(范围,1-5分)。 59名患者中有35名(59%),具有放射前门口可维修的听力(美国耳鼻喉科和颈部手术类A或B学院)在最后一次音频随访(21个月)保持维修听力。 111名患者中的两个(2%),面部神经功能HOS-BRACKMANN(HB)3级放射外科。与III等级相比,MOOS级IV预测放射线接种后的放射线肿瘤生长(P = 0.02)。治疗失败发生在119名患者中的9个(8%);失败的中位数是29个月(范围,4-70个月)。 1,3,5和7岁的肿瘤对照的精算率分别为96%,94%,88%和88%。 CKRS为声学神经瘤提供有效的肿瘤控制,具有可接受的听力保存率。需要进一步的研究来将CKRS与声学神经瘤的单级分数放射牢进行比较。 (c)2019年elestvier有限公司保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号